Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells

Cancer Research

Volumn 59, Issue 1, 1999, Pages 183-188

  Arora, Naveen ^a   Masood, Rizwan ^b   Zheng, Tong ^b   Cai, Jie ^b   Smith, D Lynne ^b   Gill, Parkash S ^b  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN VASCULOTROPIN; HYBRID PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; ENDOTHELIUM CELL; KAPOSI SARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; TUMOR VASCULARIZATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL DEATH; DIPHTHERIA TOXIN; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; IMMUNOTOXINS; LYMPHOKINES; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; SARCOMA, KAPOSI; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032943892     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Folkman, J. Seminars in Medicine of Beth Israel Hospital. Clinical applications of research in angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
2. Thomas, K. A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem., 271: 603-606, 1996.
3. Folkman, J., and D'Amore, P. A. Blood vessel formation: what is the molecular basis? Cell, 87: 1153-1155, 1996.
4. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
5. Kim, K., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 362: 841-844, 1993.
6. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 266: 11947-11954, 1991.
7. Houck, K. A., Leung, D. W., Rowland A. M., Winer, J., and Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailabilty by genetic and proteolytic mechanisms. J. Biol. Chem., 267: 26031-26037, 1992.
8. Keyt, B. A., Berleau, L. T., Nguyen, H. V., Chen, H., Heinsohn, H., Vandeln, R., and Ferrara, N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem., 271: 7788-7795, 1996.
9. I21 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J. Biol. Chem., 271: 5519-5523, 1996.
10. Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1992.
11. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Washington DC), 255: 989-991, 1992.
12. Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., and Ferrara, N. Identification of vascular endothelial growth factor determinants for binding KDR and Flt-1 receptors. J. Biol. Chem., 271: 5638-5646, 1996.
13. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
14. Storm, T. B., Anderson, P. L., Rubin-Kelley, V. E., Williams, D. P., Kiyokawa, T., and Murphy, J. R. Immunotoxins and cytokine fusion proteins. Ann. N. Y. Acad. Sci., 636: 233-250, 1991.
15. Nichlos, J., Foss, F., Kuzel, T. M., LeMaistre, C. F., Platanias, L., Ratain, M. J., Rook, A., Saleh, M., and Schwartz, G. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur. J. Cancer, 33: s34-s37, 1997.
16. Drazin, R., Kandel, J., and Collier, R. J. Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule. J. Biol. Chem., 246: 1504-1510, 1971.
17. Collier, R. J., and Kandel, J. Structure and activity of diphtheria toxin. I. Thiol dependent dissociation of a fraction of toxin into enzymatically active and inactive fragments. J. Biol. Chem., 246: 1496-1503, 1971.
18. Wilson, B. A., and Collier, R. J. Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: active-site, structure and enzymic mechanism. Curr. Top. Microbiol. Immunol., 175: 27-41, 1992.
19. Jean, L. L., and Murphy, J. R. Diphtheria toxin receptor binding domain substitution with IL-6: genetic construction and interleukin-6 receptor specific action of a diphtheria toxin-related interleukin-6 fusion protein. Protein Eng., 4: 989-994, 1991.
20. 389-interleukin-6. AIDS Res. Hum. Retrovir., 10: 969-975, 1994.
21. Masood, R., Cai, J., Zheng, T., Smith, D. L., Naidu, Y., and Gill, P. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an autocrine growth factor for AIDS-KS. Proc. Natl. Acad. Sci. USA, 94: 979-984, 1997.
22. Guan, K., and Dixon, J. E. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem., 192: 262-267, 1991.
23. Arora, N., and Leppla, S. H. Fusion of anthrax toxin and lethal factor with Shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells Infect. Immun., 62: 4955-4961, 1994.
24. Gottesman, S. Minimizing proteolysis in Escherichia coli genetic solutions. Methods Enzymol., 185: 119-129, 1990.
25. Leung, D. W., Cachianes, G., Kuang, W. J., Goddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.
26. Ramakrishnan, S., Olson, T. A., Bautch, U. L., and Mohanraj, D. Vascular endothelial growth factor toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56: 1324-1330, 1996.
27. Olson, A., Mohanraj, D., Roy, S., and Ramakrishnan, S. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int. J. Cancer, 73: 865-870, 1997.
28. Krietman, R. J., and Pastan, I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol., 6: 297-306, 1995.
29. Pai, L. H., and Pastan, I. Immunotoxin therapy for cancer. J. Am. Med. Assn., 269: 78-81, 1993.